LivaNova PLC (NASDAQ:LIVN) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its position in LivaNova PLC (NASDAQ:LIVN) by 13.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 225,439 shares of the company’s stock after selling 33,715 shares during the quarter. Russell Investments Group Ltd. owned 0.42% of LivaNova worth $11,825,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in LIVN. Ameriprise Financial Inc. boosted its position in LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after buying an additional 449,136 shares during the last quarter. Primecap Management Co. CA boosted its holdings in LivaNova by 7.3% in the third quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after purchasing an additional 395,940 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in LivaNova by 31.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company’s stock valued at $46,520,000 after purchasing an additional 208,755 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in LivaNova during the 3rd quarter worth approximately $7,932,000. Finally, Kingdon Capital Management L.L.C. acquired a new position in shares of LivaNova in the 3rd quarter valued at approximately $7,123,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Up 2.0 %

Shares of NASDAQ LIVN opened at $64.15 on Friday. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.36. The company has a market cap of $3.47 billion, a price-to-earnings ratio of -106.92 and a beta of 0.92. The company has a current ratio of 3.17, a quick ratio of 2.51 and a debt-to-equity ratio of 0.50. The stock’s 50 day simple moving average is $54.71 and its 200 day simple moving average is $51.05.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The company had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. During the same period last year, the business posted $0.43 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities research analysts expect that LivaNova PLC will post 3.01 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on LIVN shares. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Mizuho upped their target price on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. Barclays lifted their price target on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Robert W. Baird increased their target price on LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price target on shares of LivaNova in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.